Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

601 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
An oncogenic JMJD6-DGAT1 axis tunes the epigenetic regulation of lipid droplet formation in clear cell renal cell carcinoma.
Zhou J, Simon JM, Liao C, Zhang C, Hu L, Zurlo G, Liu X, Fan C, Hepperla A, Jia L, Tcheuyap VT, Zhong H, Elias R, Ye J, Henne WM, Kapur P, Nijhawan D, Brugarolas J, Zhang Q. Zhou J, et al. Among authors: elias r. Mol Cell. 2022 Aug 18;82(16):3030-3044.e8. doi: 10.1016/j.molcel.2022.06.003. Epub 2022 Jun 27. Mol Cell. 2022. PMID: 35764091 Free PMC article.
Pathologic response and surgical outcomes in patients undergoing nephrectomy following receipt of immune checkpoint inhibitors for renal cell carcinoma.
Singla N, Elias R, Ghandour RA, Freifeld Y, Bowman IA, Rapoport L, Enikeev M, Lohrey J, Woldu SL, Gahan JC, Bagrodia A, Brugarolas J, Hammers HJ, Margulis V. Singla N, et al. Among authors: elias r. Urol Oncol. 2019 Dec;37(12):924-931. doi: 10.1016/j.urolonc.2019.08.012. Epub 2019 Sep 12. Urol Oncol. 2019. PMID: 31522865 Free PMC article.
Complement as Prognostic Biomarker and Potential Therapeutic Target in Renal Cell Carcinoma.
Reese B, Silwal A, Daugherity E, Daugherity M, Arabi M, Daly P, Paterson Y, Woolford L, Christie A, Elias R, Brugarolas J, Wang T, Karbowniczek M, Markiewski MM. Reese B, et al. Among authors: elias r. J Immunol. 2020 Dec 1;205(11):3218-3229. doi: 10.4049/jimmunol.2000511. Epub 2020 Nov 6. J Immunol. 2020. PMID: 33158953 Free PMC article.
Deciphering Intratumoral Molecular Heterogeneity in Clear Cell Renal Cell Carcinoma with a Radiogenomics Platform.
Udayakumar D, Zhang Z, Xi Y, Dwivedi DK, Fulkerson M, Haldeman S, McKenzie T, Yousuf Q, Joyce A, Hajibeigi A, Notgrass H, de Leon AD, Yuan Q, Lewis MA, Madhuranthakam AJ, Sibley RC, Elias R, Guo J, Christie A, McKay RM, Cadeddu JA, Bagrodia A, Margulis V, Brugarolas J, Wang T, Kapur P, Pedrosa I. Udayakumar D, et al. Among authors: elias r. Clin Cancer Res. 2021 Sep 1;27(17):4794-4806. doi: 10.1158/1078-0432.CCR-21-0706. Epub 2021 Jul 1. Clin Cancer Res. 2021. PMID: 34210685 Free PMC article.
A renal cell carcinoma tumorgraft platform to advance precision medicine.
Elias R, Tcheuyap VT, Kaushik AK, Singla N, Gao M, Reig Torras O, Christie A, Mulgaonkar A, Woolford L, Stevens C, Kettimuthu KP, Pavia-Jimenez A, Boroughs LK, Joyce A, Dakanali M, Notgrass H, Margulis V, Cadeddu JA, Pedrosa I, Williams NS, Sun X, DeBerardinis RJ, Öz OK, Zhong H, Seshagiri S, Modrusan Z, Cantarel BL, Kapur P, Brugarolas J. Elias R, et al. Cell Rep. 2021 Nov 23;37(8):110055. doi: 10.1016/j.celrep.2021.110055. Cell Rep. 2021. PMID: 34818533 Free PMC article.
Molecular Genetic Determinants of Shorter Time on Active Surveillance in a Prospective Phase 2 Clinical Trial in Metastatic Renal Cell Carcinoma.
Reig Torras O, Mishra A, Christie A, McKenzie T, Onabolu O, Singla N, Plimack ER, Suárez C, Ornstein MC, Alpaugh RK, Elias R, Bowman IA, McKay RM, Przybycin C, Kapur P, Brugarolas J, Rini B. Reig Torras O, et al. Among authors: elias r. Eur Urol. 2022 Jun;81(6):555-558. doi: 10.1016/j.eururo.2021.12.003. Epub 2021 Dec 31. Eur Urol. 2022. PMID: 34980496 Free PMC article. Clinical Trial.
601 results